Nucleome Therapeutics

Nucleome Therapeutics is an exciting new venture that just spun out from a decade of research at Oxford University with the aim to unlock the non-coding part of the genome to help deliver life changing treatments. Our pioneering genomics platform uses the 3D structure of the genome and AI powered computational genomics to decode and mine the regulatory "dark matter" of the human genome to help deliver the next generation of genetically guided therapeutics. Our vision and commitment is shared by Oxford Sciences Innovation who backed us with a £5.2 million seed investment. We are building a passionate, creative and dedicated multi-disciplinary team of scientists with expertise in gene regulation, genomics, machine learning, data analysis and software development. Our mission is to decode and mine the regulatory "dark matter" of the human genome to transform drug target discovery and help deliver the next generation of genetically guided therapeutics.